US Representative

Randy Feenstra 2025-2026 Regular Session - Authored & Sponsored Legislation (Page 9)

Legislative Session

Primary Sponsor of Legislation

US

Us Congress 2025-2026 Regular Session

Us Congress House Bill HB578

Introduced
1/21/25  
Sarah's LawThis bill requires the Department of Justice or the Department of Homeland Security (DHS) to detain a non-U.S. national (alien under federal law) who is unlawfully present in the United States and has been charged with, arrested for, convicted of, or admits to having committed acts that constitute the essential elements of a crime that resulted in the death or serious bodily injury of another person.DHS must obtain information about the identity of any victims of the crimes for which the detained individual was charged or convicted. DHS shall provide the victim, or a relative or guardian of a deceased victim, with information about the detained individual, including name, date of birth, nationality, immigration status, criminal history, and a description of any related removal efforts.
US

Us Congress 2025-2026 Regular Session

Us Congress House Bill HB579

Introduced
1/21/25  
Refer
1/21/25  
Recruiting Families Using Data Act of 2025This bill requires state plans for child welfare services to provide for the development and implementation of a family partnership plan to improve foster care placement stability, increase rates of kinship placements, and align the composition of foster and adoptive families with the needs of children in or entering foster care.The Children's Bureau of the Administration for Children and Families also must include in its annual report information from states about the number, demographics, and characteristics of foster and adoptive families as well as a summary of the challenges related to recruiting and being foster or adoptive parents.
US

Us Congress 2025-2026 Regular Session

Us Congress House Bill HB762

Introduced
1/28/25  
Refer
1/28/25  
Snap Back Inaccurate SNAP Payments ActThis bill requires states to recoup any overpayments of benefits made to Supplemental Nutrition Assistance Program (SNAP) recipients and adjusts the formula for determining a state's liability rate for overpayments.As background, the SNAP quality control system measures how accurately SNAP state agencies determine a household’s eligibility and benefit amount and determines overpayments of benefits and underpayments. States that have comparatively high payment error rates for two consecutive years are assessed a penalty (i.e., liability amount). The Food and Nutrition Service (FNS) must use a statutory formula to determine the liability amount.Under current law, FNS must set a tolerance level for excluding small payment errors in the calculation of payment error rates (e.g., $56 or less in FY2024). This bill reduces the tolerance level for excluding small errors to $0 for FY2025 and each succeeding fiscal year.The bill also requires state agencies to recoup any overpayments of benefits made to SNAP beneficiaries.The bill adjusts the liability rate formula to reduce the state payment error rate based on the percentage of overpayments recouped by the state. Further, the bill increases the multiplier used in the liability rate formula to 25% (from 10%).

Co-Sponsor of Legislation

US

Us Congress 2025-2026 Regular Session

Us Congress House Bill HB591

Introduced
1/21/25  
Defending American Jobs and Investment Act
US

Us Congress 2025-2026 Regular Session

Us Congress House Bill HB6

Introduced
1/3/25  
Family and Small Business Taxpayer Protection Act This bill rescinds unobligated funds that were provided by the Inflation Reduction Act of 2022 to the Internal Revenue Service (IRS) for enforcement activities related to the determination and collection of taxes, for operations support for taxpayer services and enforcement activities, and for a task force to research options for a free, direct electronic filing (e-filing) tax return system. The bill also rescinds unobligated funds that were provided by the Inflation Reduction Act of 2022 for expenses of theTreasury Inspector General for Tax Administration,Office of Tax Policy,U.S. Tax Court, andoffices within the Department of the Treasury that provide oversight and support for the IRS.  
US

Us Congress 2025-2026 Regular Session

Us Congress House Bill HB624

Introduced
1/22/25  
RIFLE Act of 2025 Reining In Federal Licensing Enforcement Act of 2025
US

Us Congress 2025-2026 Regular Session

Us Congress House Bill HB632

Introduced
1/22/25  
Protecting Life on College Campus Act of 2025This bill prohibits the award of federal funds to an institution of higher education (IHE) that hosts or is affiliated with a school-based service site that provides abortion drugs or abortions to its students or to employees of the IHE or the site. An IHE that hosts or is affiliated with a site must, in order to remain eligible for federal funds, annually certify that the site does not provide abortion drugs or abortions to students or employees.
US

Us Congress 2025-2026 Regular Session

Us Congress House Bill HB649

Introduced
1/23/25  
Refer
1/23/25  
Whole Milk for Healthy Kids Act of 2025
US

Us Congress 2025-2026 Regular Session

Us Congress House Bill HB679

Introduced
1/23/25  
This bill nullifies certain changes made by the Food and Drug Administration (FDA) to dispensing requirements for mifepristone. (Mifepristone is a drug that is approved to end pregnancies through 10 weeks gestation when used in conjunction with the drug misoprostol. The procedure is often referred to as medication abortion or the abortion pill.) The FDA regulates the use of mifepristone through the Mifepristone Risk Evaluation and Mitigation Strategy (REMS) program. The program requires health care providers to comply with certain requirements in order to prescribe or dispense mifepristone to end a pregnancy; the program previously included an in-person dispensing requirement that required mifepristone to be directly dispensed to patients in clinics, medical offices, or hospitals. During the COVID-19 public health emergency, the FDA temporarily stopped enforcing the in-person dispensing requirement, which allowed mail-order pharmacies to fill and dispense mifepristone prescriptions. In January 2023, the FDA modified program requirements so as to (1) remove the in-person dispensing requirement, and (2) require pharmacies to be certified in the program in order to dispense mifepristone. The modifications allow retail pharmacies, after receiving certification, to dispense mifepristone pursuant to prescriptions that are written by program-certified prescribers. The bill nullifies the January 2023 changes and prohibits any similar changes in the future.
US

Us Congress 2025-2026 Regular Session

Us Congress House Bill HB682

Introduced
1/23/25  
Heartbeat Protection Act of 2025
US

Us Congress 2025-2026 Regular Session

Us Congress House Bill HB685

Introduced
1/23/25  
Support And Value Expectant Moms and Babies Act of 2025 or the SAVE Moms and Babies Act of 2025This bill prohibits the Food and Drug Administration (FDA) from approving any new drug (either as a brand-name drug or a generic) intended to terminate a pregnancy and imposes additional restrictions on such drugs that are already approved.Under the bill, an already-approved drug intended to terminate a pregnancy may be dispensed to a patient only with a prescription. Furthermore, the FDA may not approve any labeling change that would authorize (1) using the drug after 70 days of gestation, or (2) dispensing the drug by any means other than in-person administration by the prescribing health care practitioner.The FDA must also impose additional restrictions on such already-approved drugs, including by (1) requiring the prescribing health care practitioner to receive a special certification, (2) prohibiting the practitioner from also acting as the dispensing pharmacist, and (3) requiring the practitioner to have the ability to provide surgical intervention to the patient.The bill also rescinds any investigational use exemption already granted to such a drug if the bill would have prohibited the FDA from granting the exemption. (Currently, the FDA may grant an exemption to certain market approval requirements if a drug is intended solely for use in safety and effectiveness investigations.)
US

Us Congress 2025-2026 Regular Session

Us Congress House Bill HB7

Introduced
1/22/25  
No Taxpayer Funding for Abortion and Abortion Insurance Full Disclosure Act of 2025
US

Us Congress 2025-2026 Regular Session

Us Congress House Bill HB703

Introduced
1/23/25  
Main Street Tax Certainty Act
US

Us Congress 2025-2026 Regular Session

Us Congress House Bill HB719

Introduced
1/24/25  
No Abortion Coverage for Medicaid ActThis bill prohibits the Centers for Medicare & Medicaid Services from approving experimental, pilot, or demonstration projects under Medicaid (also known as Section 1115 Demonstrations) if the project provides federal financial assistance for abortions or for health benefits that include abortions, including expenses for related travel or lodging.The bill's restrictions do not apply to abortions in the cases of rape or incest; treatments to address life-threatening physical disorders, injuries, or illnesses; or treatments for miscarriages or ectopic pregnancies.
US

Us Congress 2025-2026 Regular Session

Us Congress House Bill HB722

Introduced
1/24/25  
Life at Conception Act